174 related articles for article (PubMed ID: 35338582)
1. Evaluation of CYP1A2 activity: Relationship between the endogenous urinary 6-hydroxymelatonin to melatonin ratio and paraxanthine to caffeine ratio in dried blood spots.
Magliocco G; Desmeules J; Samer CF; Thomas A; Daali Y
Clin Transl Sci; 2022 Jun; 15(6):1482-1491. PubMed ID: 35338582
[TBL] [Abstract][Full Text] [Related]
2. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study.
Härtter S; Ursing C; Morita S; Tybring G; von Bahr C; Christensen M; Röjdmark S; Bertilsson L
Clin Pharmacol Ther; 2001 Jul; 70(1):10-6. PubMed ID: 11452239
[TBL] [Abstract][Full Text] [Related]
3. Why dried blood spots are an ideal tool for CYP1A2 phenotyping.
De Kesel PM; Lambert WE; Stove CP
Clin Pharmacokinet; 2014 Aug; 53(8):763-71. PubMed ID: 24980692
[TBL] [Abstract][Full Text] [Related]
4. Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
De Kesel PM; Lambert WE; Stove CP
Clin Pharmacokinet; 2015 Jul; 54(7):771-81. PubMed ID: 25603821
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.
Perera V; Gross AS; Xu H; McLachlan AJ
J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488
[TBL] [Abstract][Full Text] [Related]
6. Calculation of Human Melatonin Partial Metabolic Clearance in Healthy Adult Volunteers for Investigation of a Novel in Vivo CYP1A2 Phenotyping Method: A Pilot Study.
Ohki S; Ogawa S; Takano H; Shimazaki H; Fukae M; Furihata T; Shibasaki H; Yokokawa A
Biol Pharm Bull; 2023; 46(5):736-740. PubMed ID: 37121701
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations.
Fuhr U; Rost KL; Engelhardt R; Sachs M; Liermann D; Belloc C; Beaune P; Janezic S; Grant D; Meyer UA; Staib AH
Pharmacogenetics; 1996 Apr; 6(2):159-76. PubMed ID: 9156694
[TBL] [Abstract][Full Text] [Related]
8. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans.
Rasmussen BB; Brøsen K
Br J Clin Pharmacol; 1997 Mar; 43(3):253-8. PubMed ID: 9088579
[TBL] [Abstract][Full Text] [Related]
9. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity.
Härtter S; Nordmark A; Rose DM; Bertilsson L; Tybring G; Laine K
Br J Clin Pharmacol; 2003 Dec; 56(6):679-82. PubMed ID: 14616429
[TBL] [Abstract][Full Text] [Related]
10. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.
Fuhr U; Rost KL
Pharmacogenetics; 1994 Jun; 4(3):109-16. PubMed ID: 7920690
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous determination of melatonin and 6-hydroxymelatonin in human overnight urine by LC-MS/MS.
Magliocco G; Le Bloc'h F; Thomas A; Desmeules J; Daali Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Sep; 1181():122938. PubMed ID: 34521018
[TBL] [Abstract][Full Text] [Related]
12. The determination of the Paraxanthine/Caffeine ratio as a metabolic biomarker for CYP1A2 activity in various human matrices by UHPLC-ESIMS/MS.
Lajin B; Schweighofer N; Goessler W; Obermayer-Pietsch B
Talanta; 2021 Nov; 234():122658. PubMed ID: 34364467
[TBL] [Abstract][Full Text] [Related]
13. Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2.
Labedzki A; Buters J; Jabrane W; Fuhr U
Biochem Pharmacol; 2002 Jun; 63(12):2159-67. PubMed ID: 12110375
[TBL] [Abstract][Full Text] [Related]
14. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma.
Perera V; Gross AS; McLachlan AJ
Biomed Chromatogr; 2010 Oct; 24(10):1136-44. PubMed ID: 20853468
[TBL] [Abstract][Full Text] [Related]
15. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction.
Abraham K; Geusau A; Tosun Y; Helge H; Bauer S; Brockmöller J
Clin Pharmacol Ther; 2002 Aug; 72(2):163-74. PubMed ID: 12189363
[TBL] [Abstract][Full Text] [Related]
16. Assessment of CYP1A2 activity in clinical practice: why, how, and when?
Faber MS; Jetter A; Fuhr U
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):125-34. PubMed ID: 16128905
[TBL] [Abstract][Full Text] [Related]
17. Validation of a high-performance liquid chromatography assay for quantification of caffeine and paraxanthine in human serum in the context of CYP1A2 phenotyping.
Koch JP; ten Tusscher GW; Koppe JG; Guchelaar HJ
Biomed Chromatogr; 1999 Jun; 13(4):309-14. PubMed ID: 10416066
[TBL] [Abstract][Full Text] [Related]
18. Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities.
Fuchs P; Haefeli WE; Ledermann HR; Wenk M
Eur J Clin Pharmacol; 1999 Jan; 54(11):869-76. PubMed ID: 10027663
[TBL] [Abstract][Full Text] [Related]
19. Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio.
Doude van Troostwijk LJ; Koopmans RP; Guchelaar HJ
Fundam Clin Pharmacol; 2003 Jun; 17(3):355-62. PubMed ID: 12803575
[TBL] [Abstract][Full Text] [Related]
20. Contribution of CYP1A2 in the hepatic metabolism of melatonin: studies with isolated microsomal preparations and liver slices.
Skene DJ; Papagiannidou E; Hashemi E; Snelling J; Lewis DF; Fernandez M; Ioannides C
J Pineal Res; 2001 Nov; 31(4):333-42. PubMed ID: 11703563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]